TSA Updates Medical Marijuana Travel Guidelines; Experts Warn Against In-Flight Use
The TSA has updated its guidelines to allow passengers to travel with medical marijuana in carry-on and checked bags for use at their destination. Health experts caution against using cannabis during flights, citing cardiovascular risks when combined with altitude and the unpredictability of dosing in unfamiliar environments. The guidance emphasizes that TSA clearance does not provide legal protection from state or local law enforcement.
The Transportation Security Administration has clarified its policy on medical marijuana travel, permitting patients to transport cannabis for medical purposes to their destination. However, experts strongly recommend against using cannabis during flights, citing research from the American College of Cardiology showing that cannabis use alters heart rhythm and increases oxygen demand—risks that compound at high altitudes where the body already experiences reduced oxygen. Cannabis expert Rob Mejia advises that unfamiliar doses or new products should never be tested in airports or on planes, as reactions can range from mild relaxation to severe nausea, dizziness, and hyperventilation. Travelers are warned that TSA approval does not shield them from state or local law enforcement, and that professionally packaged, labeled products are less likely to raise questions than loose cannabis. International travel with cannabis carries significantly greater legal risks and is not recommended, even in countries where cannabis is legal.
What's missing
The article does not specify the exact date of the TSA's guideline update or provide a direct link to the updated TSA guidance. Additionally, while the article cites research on cardiovascular effects, it does not mention the specific study details or sample sizes from the American College of Cardiology research referenced.
What different sources said
- New York PostRight
Flying with cannabis? TSA’s new guidance comes with a major health warning
Related
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.
AI's Growing Role in Clinical Trials Depends on Skilled Implementation
Artificial intelligence is being integrated across clinical trials for drug discovery, patient selection, protocol design, and data management. The technology shows particular promise for rare disease research through AI-powered artificial twins that could replace traditional placebo controls. However, experts emphasize that AI tools are only effective when properly implemented by trained personnel who prioritize patient outcomes over technological advancement.
US Suicide Deaths Fall Nationally, but Several States See Sharp Increases
National suicide deaths fell 3% between 2023-2024, but New Hampshire experienced a 12% increase, with Iowa, Connecticut, and South Carolina also seeing double-digit or near double-digit rises. The report from Trust for America's Health notes that rural areas tend to have higher suicide rates, though the specific causes of state-level variations remain unclear. Regional disparities persist, with the Midwest showing the highest suicide rates and the Northeast the lowest, though all regions have increased substantially since 2004.